Morgan Stanley lowered the firm’s price target on Elevance Health (ELV) to $316 from $428 and keeps an Equal Weight rating on the shares. While reduced 2025 guidance was expected, the lack of clarity into 2026 is “concerning” in light of Medicaid and exchange trend headwinds that “could prove more enduring,” the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- ACA marketplace plans seek double digit rate increases for 2026, WSJ says
- Elevance Health price target lowered to $358 from $434 at Barclays
- U.S. Health insurers prescription drug denials on the rise, NYT says
- Elevance Health Reports Strong Revenue Growth in Q2 2025
- Elevance Health Earnings Call: Growth Amid Challenges